The ASX biotech sector dipped slightly in value in May, but stocks such as Medadvisor and Dimerix recorded lusty gains.

The ASX gained 0.65pc in early trading, showing resilience as global markets largely shrug off renewed tariff concerns from the US.

A leading fund manager expects more upside from this surging ASX 300 stock. The post Buy this surging ASX 300 stock before ...

These stocks could be leading opportunities according to one expert. The post 2 ASX 300 shares to buy this month: experts ...

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...

In morning trade, the ASX 300 stock is down 3.5% to $8.18. This compares to a 0.45% decline by the ASX 200 index. Investors have been selling the computer hardware and software distributor's ...

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...

Both the VAS and A200 ETF track an index meaning they are passively managed. VAS’s strategy aims to fully replicate the ASX 300, a free-float-adjusted, market-cap-weighted index. The ASX 300 covers ...

On Wall Street, the S&P 500 index ended flat and the Dow Jones indexes dipped 0.2 per cent, while the technology-focused Nasdaq rose 0.7 per cent. Cryptocurrency ...

Wall Street’s flying but the ASX skids this morning. Life360 rockets again, while stocks like Macquarie and Aristocrat stumble. The local slump stood in contrast to a cracking session on Wall ...

Don't miss out on the headlines from Stockhead. Followed categories will be added to My News. ASX cools off after five-day sprint Wall Street tech stocks roar back to life The local slump stood in ...